Summary of COVID-19 obefazimod studies
Hide extended summaries
RCT 509 patients with COVID-19 at risk for severe disease showing no benefit with obefazimod (ABX464) 50mg daily for 28 days.
Nov 2023, J. Allergy and Clinical Immunology: Global, https://www.sciencedirect.com/science/article/pii/S2772829323000656, https://c19p.org/giavinabianchi
1. Giavina-Bianchi et al., ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial
305 patient obefazimod late treatment RCT: 26% higher ventilation (p=0.81) and 139% higher need for oxygen therapy (p=0.11).RCT 509 patients with COVID-19 at risk for severe disease showing no benefit with obefazimod (ABX464) 50mg daily for 28 days.
Nov 2023, J. Allergy and Clinical Immunology: Global, https://www.sciencedirect.com/science/article/pii/S2772829323000656, https://c19p.org/giavinabianchi
Please send us corrections, updates, or comments.
c19early involves the extraction of 200,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.